Clinical Validation and Implementation of a Measurable Residual Disease Assay for NPM1 in Acute Myeloid Leukemia by Error-Corrected Next-Generation Sequencing.
Ritterhouse LL, Parilla M, Zhen CJ, Wurst MN, Puranik R, Henderson CM, Joudeh NZ, Hartley MJ, Haridas R, Wanjari P, Furtado LV, Kadri S, Segal JP. Clinical Validation and Implementation of a Measurable Residual Disease Assay for NPM1 in Acute Myeloid Leukemia by Error-Corrected Next-Generation Sequencing. Mol Diagn Ther. 2019 Dec; 23(6):791-802.
PMID: 31673932
Next generation sequencing identifies two Genomically distinct groups among pyloric gland adenomas.
Setia N, Wanjari P, Yassan L, Niu N, Kadri S, Ritterhouse L, Misdraji J, Brown I, Segal J, Hart J. Next generation sequencing identifies two Genomically distinct groups among pyloric gland adenomas. Hum Pathol. 2019 Nov 26.
PMID: 31783043
Secondary resistance to immunotherapy associated with ß-catenin pathway activation or PTEN loss in metastatic melanoma.
Trujillo JA, Luke JJ, Zha Y, Segal JP, Ritterhouse LL, Spranger S, Matijevich K, Gajewski TF. Secondary resistance to immunotherapy associated with ß-catenin pathway activation or PTEN loss in metastatic melanoma. J Immunother Cancer. 2019 Nov 08; 7(1):295.
PMID: 31703593
Measurable residual disease monitoring for patients with acute myeloid leukemia following hematopoietic cell transplantation using error corrected hybrid capture next generation sequencing.
Balagopal V, Hantel A, Kadri S, Steinhardt G, Zhen CJ, Kang W, Wanjari P, Ritterhouse LL, Stock W, Segal JP. Measurable residual disease monitoring for patients with acute myeloid leukemia following hematopoietic cell transplantation using error corrected hybrid capture next generation sequencing. PLoS One. 2019; 14(10):e0224097.
PMID: 31658273
Fewer actionable mutations but higher tumor mutational burden characterizes NSCLC in black patients at an urban academic medical center.
Choudhury NJ, Eghtesad M, Kadri S, Cursio J, Ritterhouse L, Segal J, Husain A, Patel JD. Fewer actionable mutations but higher tumor mutational burden characterizes NSCLC in black patients at an urban academic medical center. Oncotarget. 2019 Oct 08; 10(56):5817-5823.
PMID: 31645901
Germline BRCA-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity.
de Jonge MM, Ritterhouse LL, de Kroon CD, Vreeswijk MPG, Segal JP, Puranik R, Hollema H, Rookus MA, van Asperen CJ, van Leeuwen FE, Smit VTHBM, Howitt BE, Bosse T. Germline BRCA-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity. Clin Cancer Res. 2019 Sep 06.
PMID: 31492746
Genetic Underpinnings of Renal Cell Carcinoma With Leiomyomatous Stroma.
Parilla M, Alikhan M, Al-Kawaaz M, Patil S, Kadri S, Ritterhouse LL, Segal J, Fitzpatrick C, Antic T. Genetic Underpinnings of Renal Cell Carcinoma With Leiomyomatous Stroma. Am J Surg Pathol. 2019 Aug; 43(8):1135-1144.
PMID: 30986793
High NPM1 mutant allele burden at diagnosis correlates with minimal residual disease at first remission in de novo acute myeloid leukemia.
Patel SS, Pinkus GS, Ritterhouse LL, Segal JP, Dal Cin P, Restrepo T, Harris MH, Stone RM, Hasserjian RP, Weinberg OK. High NPM1 mutant allele burden at diagnosis correlates with minimal residual disease at first remission in de novo acute myeloid leukemia. Am J Hematol. 2019 Aug; 94(8):921-928.
PMID: 31148220
Quantitative next-generation sequencing-based analysis indicates progressive accumulation of microsatellite instability between atypical hyperplasia/endometrial intraepithelial neoplasia and paired endometrioid endometrial carcinoma.
Chapel DB, Patil SA, Plagov A, Puranik R, Mendybaeva A, Steinhardt G, Wanjari P, Lastra RR, Kadri S, Segal JP, Ritterhouse LL. Quantitative next-generation sequencing-based analysis indicates progressive accumulation of microsatellite instability between atypical hyperplasia/endometrial intraepithelial neoplasia and paired endometrioid endometrial carcinoma. Mod Pathol. 2019 Oct; 32(10):1508-1520.
PMID: 31186530
Targeted mutational analysis of inflammatory bowel disease-associated colorectal cancers.
Alpert L, Yassan L, Poon R, Kadri S, Niu N, Patil SA, Mujacic I, Montes D, Galbo F, Wurst MN, Zhen CJ, Cohen RD, Rubin DT, Pekow JR, Weber CR, Xiao SY, Hart J, Segal J, Setia N. Targeted mutational analysis of inflammatory bowel disease-associated colorectal cancers. Hum Pathol. 2019 Jul; 89:44-50.
PMID: 31054900